10-Q: Cardiff Oncology Reports Second Quarter 2024 Financial Results and Clinical Trial Updates

Cardiff Oncology's Q2 2024 report details financial results, clinical trial progress, and a focus on their lead drug candidate, onvansertib.

Summary

• Cardiff Oncology reported a net loss of $11.8 million for the three months ended June 30, 2024, and $21.8 million for the six months ended June 30, 2024.
• The company's cash, cash equivalents, and short-term investments totaled $60.3 million as of June 30, 2024.
• Royalty revenues were $163,000 for the three months and $368,000 for the six months ended June 30, 2024.
• Research and development expenses were $9.5 million for the three months and $17.5 million for the six months ended June 30, 2024.
• Selling, general, and administrative expenses were $3.2 million for the three months and $6.3 million for the six months ended June 30, 2024.
• The company believes it has sufficient cash to meet its funding requirements for at least the next 12 months.
• Cardiff Oncology is advancing clinical trials for onvansertib, including a Phase 2 trial in first-line RAS-mutated metastatic colorectal cancer (mCRC) and investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple-negative breast cancer (TNBC).
• The company expects to release initial data from the CRDF-004 trial in the second half of 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive clinical trial updates and a strong cash position, the company is still incurring significant losses and needs to raise additional capital. The clinical results are promising but not yet conclusive, and the company faces significant risks.

Positives

• The company has a strong cash position of $60.3 million, which is expected to fund operations for at least the next 12 months.
• Onvansertib has shown promising results in clinical trials, particularly in bevacizumab-naive patients with mCRC.
• The company is actively pursuing multiple clinical trials across different cancer types.
• The company is collaborating with Pfizer Ignite for the CRDF-004 trial.
• The company has received FDA approval for NALIRIFOX as a first-line treatment option for mPDAC, which will be used in a new trial.

Negatives

• The company has incurred significant net losses, with a net loss of $21.8 million for the six months ended June 30, 2024.
• The company has negative operating cash flows.
• The company is reliant on raising additional capital to fund its operations.
• The company's short-term investments portfolio and money market accounts have decreased, leading to lower interest income.
• The ONSEMBLE trial showed objective responses only in bevacizumab-naive patients, indicating a potential limitation of the drug's efficacy in certain patient populations.

Risks

• The company is subject to the risks associated with clinical-stage biotechnology companies, including the uncertainty of clinical trial outcomes and regulatory approvals.
• The company may not be able to raise additional capital on acceptable terms, or at all, which could impact its ability to continue operations.
• The company faces competition from other companies developing cancer therapies.
• The company's clinical trials may not be successful, and the company's drug candidates may not receive regulatory approval.
• The company's financial performance is dependent on the success of its clinical trials and the commercialization of its drug candidates.

Future Outlook

The company expects to release initial data from the CRDF-004 trial in the second half of 2024 and believes it has sufficient cash to meet its funding requirements for at least the next 12 months. The company anticipates needing additional capital to further advance its clinical trial programs and support its other operations.

Management Comments

• Management believes the company has sufficient cash to meet its funding requirements for at least the next 12 months.
• Management expects to continue to incur losses and require additional capital to further advance its clinical trial programs and support its other operations.

Industry Context

Cardiff Oncology is operating in the competitive oncology therapeutics market, focusing on PLK1 inhibition. The company's approach of combining onvansertib with standard-of-care therapies aligns with the industry trend of combination therapies to overcome treatment resistance. The company's focus on specific tumor vulnerabilities and biomarker assays is also in line with the industry's move towards personalized medicine.

Comparison to Industry Standards

• The reported 29% ORR in the TROV-054 trial for KRAS-mutated mCRC compares favorably to historical control trials of FOLFIRI with bevacizumab, which have shown ORR of 5-13%.
• The median progression-free survival (mPFS) of 9.3 months in the TROV-054 trial is also higher than the historical control of 4.5-6.7 months.
• The 19% ORR in the CRDF-001 trial for mPDAC is higher than the historical control of 7.7% in the second-line setting.
• These results suggest that onvansertib may offer a clinical benefit over standard-of-care treatments in these specific patient populations.
• Companies like Amgen, with their KRAS inhibitor Lumakras, and Mirati Therapeutics, with Krazati, are also targeting KRAS-mutated cancers, but Cardiff's approach is different, focusing on PLK1 inhibition in combination with standard therapies.

Corporate Governance

Legal Proceedings

• A purported stockholder filed a class action and derivative complaint against the company and certain directors, alleging issues with the company's By-Laws and the validity of certain director elections and equity plan amendments.
• The complaint was dismissed with prejudice as to the plaintiff on June 26, 2024, with the court retaining jurisdiction to determine plaintiffs counsel's application for an award of attorneys fees.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• Employees may be impacted by changes in stock-based compensation and potential restructuring.
• Patients may benefit from the development of new cancer therapies.
• The company's financial performance may impact its ability to meet its obligations to suppliers and creditors.

Next Steps

• The company plans to release initial data from the CRDF-004 trial in the second half of 2024.
• The company is planning to support a new investigator-initiated mPDAC Phase 2 trial of onvansertib in combination with first-line SoC NALIRIFOX.
• The company will continue to advance its other clinical programs, including the trials in SCLC and TNBC.

Key Dates

Keywords

Onvansertib, PLK1 inhibitor, Colorectal cancer, Pancreatic cancer, Clinical trials, Metastatic cancer, Biotechnology, RAS-mutated, mCRC, mPDAC, SCLC, TNBC